UroGen Pharma Ltd | 8-K: UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
UroGen Pharma Ltd | 8-K: UroGen Pharma Ahead of Schedule to Complete UGN-102 NDA Submission and Reports 2024 Second Quarter Financial Results and Business Highlights
烏龍製藥 | 8-K：UroGen Pharma 提前完成 UGN-102 保密協議的提交和報告 2024 年第二季度財務業績和業務亮點
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。